Additional longer-term efficacy and safety data from the ongoing TIDES trial with Takeda Pharmaceutical Co. Ltd.’s dengue vaccine TAK-003 show generally consistent results with those from the recently published 12-month follow-up, but there was a fall in efficacy with time and again relatively lower effectiveness against serotype 3.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?